PURPOSE: In 1996, the Japan Wilms Tumor Study (JWiTS) group was founded to elucidate the efficacy and safety of the regimen established by the National Wilms Tumor Study (NWTS) group in the USA, and a multicenter cooperative study (JWiTS-1) was started in Japan. This report reviews the results of JWiTS-1. METHODS: A total of 307 patients with malignant renal tumor were enrolled in the JWiTS-1 study between 1996 and 2005. Central pathological diagnosis and follow-up data were available in 210 cases. The protocol regimens were similar to the NWTS-5 regimens. Clinical stage was classified according to the Japanese Staging System. RESULTS: Five-year overall survival (OS) rate was 91.1% for nephroblastoma, 72.9% for clear cell sarcoma of the kidney (CCSK), and 22.2% for rhabdoid tumor of the kidney (RTK). In the nephroblastoma patients, 5-year OS was 90.5% for stage I disease, 92.2% for stage II, 90.9% for stage III, 86.7% for stage IV, and 78.7% for stage V. CONCLUSIONS: The OS of patients in the JWiTS-1 study were comparable with the results of other multicenter studies in the USA and Europe. The outcome for patients with nephroblastoma and CCSK was fair. In contrast, the cure rate for those with RTK was not satisfactory. New treatment strategies are needed for patients with RTK.
PURPOSE: In 1996, the Japan Wilms Tumor Study (JWiTS) group was founded to elucidate the efficacy and safety of the regimen established by the National Wilms Tumor Study (NWTS) group in the USA, and a multicenter cooperative study (JWiTS-1) was started in Japan. This report reviews the results of JWiTS-1. METHODS: A total of 307 patients with malignant renal tumor were enrolled in the JWiTS-1 study between 1996 and 2005. Central pathological diagnosis and follow-up data were available in 210 cases. The protocol regimens were similar to the NWTS-5 regimens. Clinical stage was classified according to the Japanese Staging System. RESULTS: Five-year overall survival (OS) rate was 91.1% for nephroblastoma, 72.9% for clear cell sarcoma of the kidney (CCSK), and 22.2% for rhabdoid tumor of the kidney (RTK). In the nephroblastomapatients, 5-year OS was 90.5% for stage I disease, 92.2% for stage II, 90.9% for stage III, 86.7% for stage IV, and 78.7% for stage V. CONCLUSIONS: The OS of patients in the JWiTS-1 study were comparable with the results of other multicenter studies in the USA and Europe. The outcome for patients with nephroblastoma and CCSK was fair. In contrast, the cure rate for those with RTK was not satisfactory. New treatment strategies are needed for patients with RTK.
Authors: Christopher Mitchell; Kathy Pritchard-Jones; Rosemary Shannon; Carolyn Hutton; Suzanne Stevens; David Machin; John Imeson; Anna Kelsey; Gordan M Vujanic; Peter Gornall; Jenny Walker; Roger Taylor; Pat Sartori; Juliet Hale; Gill Levitt; Boo Messahel; Helen Middleton; Richard Grundy; Jon Pritchard Journal: Eur J Cancer Date: 2006-08-10 Impact factor: 9.162
Authors: D M Green; N E Breslow; J B Beckwith; M L Ritchey; R C Shamberger; G M Haase; G J D'Angio; E Perlman; M Donaldson; P E Grundy; R Weetman; M J Coppes; M Malogolowkin; P Shearer; P Coccia; M Kletzel; P R Thomas; R Macklis; G Tomlinson; V Huff; R Newbury; D Weeks Journal: J Clin Oncol Date: 2001-09-01 Impact factor: 44.544
Authors: A Weirich; I Leuschner; D Harms; G M Vujanic; J Tröger; U Abel; N Graf; D Schmidt; R Ludwig; P A Voûte Journal: Ann Oncol Date: 2001-03 Impact factor: 32.976
Authors: B T Montgomery; P P Kelalis; M L Blute; E J Bergstralh; J B Beckwith; P Norkool; D M Green; G J D'Angio Journal: J Urol Date: 1991-08 Impact factor: 7.450
Authors: Saskia L Gooskens; Norbert Graf; Rhoikos Furtwängler; Filippo Spreafico; Christophe Bergeron; Gema L Ramírez-Villar; Jan Godzinski; Christian Rübe; Geert O Janssens; Gordan M Vujanic; Ivo Leuschner; Aurore Coulomb-L'Hermine; Anne M Smets; Beatriz de Camargo; Sara Stoneham; Harm van Tinteren; Kathy Pritchard-Jones; Marry M van den Heuvel-Eibrink Journal: Nat Rev Urol Date: 2018-02-27 Impact factor: 14.432